Introduction

B-cell chronic lymphocytic leukemia (B-CLL) is a quite unique cancer characterized by a progressive accumulation of quiescent CD19
þ CD5 þ CD23 þ B-cell clones in the blood, bone marrow and lymphoid tissues. This disease is still considered as incurable, despite the introduction of Fludarabinebased combinations. Indeed, Fludarabine yields high response rates when combined with monoclonal antibodies or other drugs as first-line therapy, [1] [2] [3] but does not avoid the mostly invariable relapses 4 due to progressive outgrowth of B-CLL cells increasingly resistant to the successive lines of therapy. A complete eradication of the leukemic clone is therefore mandatory to definitively stop the striking evolution of the B-CLL disease. To this aim, a better knowledge of the innate and acquired cellular pathways leading to B-CLL chemoresistance is warranted.
In the past, B-CLL chemoresistance has been attributed to intrinsic apoptotic defects 5, 6 and to both genuine and adaptive (drug-induced) activity of the MDR1/ABCB1 protein. 7 In this study, we hypothesized that the progressive development of B-CLL chemoresistance might result from dynamics of heterogeneous chemoresistant cell subsets in addition to the mere acquisition of an enzymatic activity. More precisely, posttherapeutic B-CLL relapse could uncover a hierarchical organization of the whole B-CLL cell population, in which a discrete and multiresistant leukemic cell compartment repeatedly replenishes the main chemosensitive B-CLL cell population after treatment(s).
A very minor cell compartment from various tumors [8] [9] [10] [11] [12] [13] and normal tissues [14] [15] [16] [17] comprises naturally chemoresistant (ABCG2 þ ) cells, with high dye-efflux capacity, that are referred to as 'side population' (SP) cells. 14, 18 Although sorting the SP cells usually enriches for a subset displaying stemness features, 8, [9] [10] [11] [12] [13] 14, 18 this phenotype is not only exclusively restricted to stem cells 19 but also shared by some differentiated cells. 20, 21 In this study, we tracked chemoresistant subsets of B-CLL cells by the SP technique to clarify the dynamics of chemoresistance in this disease. Our study confirms the existence of Fludarabine-resistant leukemic SP cells in B-CLL, as established recently by Foster et al. 22 In addition to uncovering both innate and acquired cell compartments with SP phenotype, this report addresses the question of polyresistance displayed by the B-CLL SP cells and demonstrates the prevalence of this population in post-therapeutic B-CLL samples. Finally, this study attempted to characterize SP cell dynamics underlying successive B-CLL relapses with progressive chemoresistance. Thus, both innate and acquired SP cells represent as major actors of the B-CLL pathogenesis and important therapeutic targets.
Methods
B-CLL samples and culture
Peripheral blood samples were collected from 22 untreated and 5 previously treated B-CLL patients after obtaining informed consents and approval from the Toulouse University Medical Center Ethic Committee. B-CLL diagnosis was carried out by morphology and immunophenotype (Matutes score of 4/5). Briefly, mononuclear cells were separated by Ficoll centrifugation and analyzed or purified for SP by flow cytometry. For western blotting experiments, B-leukemic cells were purified by magnetic separation according to the manufacturer's instructions (Stem cell Technologies, Grenoble, France). For in vitro treatments, cells were cultured in RPMI containing 10% fetal calf serum at 1 Â 10 6 cells/ml in the presence or absence of 
Flow cytometry
On the basis of the protocol designed by Goodell et al., 14 primary B-CLL cells were stained with 5 mg/ml of Hoechst 33342 dye (Invitrogen) with or without pre-incubation with ABC transporter inhibitors (Verapamil, Fumitremorgin C and Reserpine) (Sigma) during 90 min at 37 1C under agitation. Subsequently, cells were incubated on ice with anti-CD19-FITC (Beckman Coulter, Roissy, France) and anti-CD5-PC7 (Clinisciences, Montrouge, France) antibodies in combination with one of the following phycoerythrin-labeled antibodies: anti-k light chain, anti-l light chain (from DakoCytomation, Trappes, France), anti-CD38, anti-CD34, anti-CD3, anti-CD56 (all from Beckman Coulter) and anti-CD23 (Clinisciences). Before fluorescent-activated cell sorting analysis, cells were stained with 2 mg/ml of 7-amino-actinomycin D (BD Pharmingen, Le Pont de Claix, France). Data acquisitions were performed on a BD LSR II cytometer (BD Bioscience, Le Pont de Claix, France). Flow cytometry acquisitions were analyzed using BD FACSDiva (BD Bioscience) and FlowJo softwares (Treestar, Ashland, OR, USA). 
Cell sorting
Interphasic fluorescence in situ hybridization
Fluorescence in situ hybridization experiments were performed with P53/SE17, DLEU(13q14)/13qter and SE12(D12Z1) probes (Kreatech, Amsterdam, The Netherlands) on cytospin of SP and non-SP/Bulk cells, according to the manufacturer's recommendations.
Western blot
Primary B-leukemic cells (Bulk B-CLL) for western blotting were obtained by negative purification with magnetic beads (Human B-cell enrichment kit without CD43 depletion, Stem cell technologies, Grenoble, France). SP cells (SP Fludarabine) were obtained by treatment with Fludarabine during 7 days and subsequent sorting of 7-amino-actinomycin D/CD56/CD3/ Hoechst 33342-negative phenotype. Cells were then washed with cold phosphate-buffered saline and resuspended into Laemli buffer Â 1. The protein extracts were processed according to western blot standard procedure. The different antibodies used in this study were as follows: anti-BMI-1 (Ozyme, Saint-Quentin en Yvelines, France), anti-ABCG2 (Abcam, Paris, France) and a-tubulin (Sigma). Horseradish peroxidaseconjugated secondary antibodies against rabbit, rat or mouse immunoglobulins were from Jackson Immunoresearch Laboratories (Jackson Immunoresearch Laboratories, Suffolk, UK).
Statistical analysis
Student's paired t-test was used to determine differences between paired samples, with cutoff a ¼ 5%. Values were expressed as means±s.d.
Results
Characterizing B-CLL-derived innate SP cells
We assessed the percentage of cells with SP phenotype in blood samples obtained from several (n ¼ 22) newly diagnosed (previously untreated) B-CLL patients by measuring Hoechst 33342 efflux through ultraviolet laser-based flow cytometry. This analysis evidenced a minor proportion of SP cells in every sample (median rate of SP cells among total cells ¼ 0.035%, range: 0.01-0.39%) ( Figure 1a , Table 1 ). The SP phenotype was abrogated on cell treatment with the ABC transporter inhibitors verapamil (80 mM) (Figure 1a ), fumitremorgin C (5 mM) and reserpin (50 mM) (not shown). Total SP cells in every sample In the aim of identifying a specific marker of B-CLL SP cells, we compared the leukemic fraction (CD19 þ CD5 þ -gated cells) of SP and non-SP cells in each sample for expression of markers typically characterizing poor prognosis in B-CLL (CD38) and immature phenotypes (CD34). Expression of CD38 was analyzed separately on CD38 þ (more than 30% of positive cells) and CD38
À patients. For CD38 þ patients only, SP cells displayed an overall increase of CD38 expression compared with their non-SP counterpart. This trend was reproducible for the three patients tested, although no significance was found ( Figure 1c ). No differences were observed for CD34 expression ( Figure 1c ) and CD127 (not shown).
The phenotype of SP cells strongly suggested their leukemic nature. Nevertheless, to check for clonality of B-CLL SP cells, the SP cells sorted from (del 13q14, del p17 and þ 12) B-CLL patients were analyzed by fluorescence in situ hybridization. We found identical cytogenetic alterations in both bulk and SP leukemic cells in all patients tested (Figure 1d ), confirming that SP cells belongs to the leukemic clone.
Together, these data indicated that in the absence of any treatment, all B-CLL samples comprise a minorFyet sizeableF proportion of natural SP cells, which display the same phenotypic and cytogenetic profiles as the whole B-CLL population, suggesting that they are innate B-CLL SP cells.
B-CLL treatments select SP cells
We next asked whether the B-CLL chemotherapy selects for SP cells, by treating B-CLL blood samples with either Fludarabine (2 mg/ml, 7 days, n ¼ 18), Bendamustin (50 mg/ml, 3 days, n ¼ 7), or Rituximab (10 mg/ml, 7 days, n ¼ 3) before measuring their (Figure 2a ), on average of B2.5-fold with Rituximab and 1000-fold with Fludarabine or Bendamustin (Figure 2b ). We noticed a global chemoresistance of the whole B-CLL cells (both SP and non-SP) in 2/18 and 2/7 patients for Fludarabine and Bendamustin respectively (not shown). Nevertheless as expected, Fludarabine and Bendamustin induced a massive destruction of the vast majority of B-CLL cells, although SP phenotype analysis of the few drug-surviving cells evidenced a highly selective destruction of the non-SP compartment by all treatments (Figure 2a ).
Molecular validation of this exclusive SP phenotype was given by the overexpression of ABCG2 by Fludarabine-resistant SP cells, in complete accordance with the described SP phenotype. 20 In addition, Fludarabine-resistant SP cells had strongly upregulated BMI-1 expression (Figure 2c ).
To check whether non-SP cells evolved by an adaptive switch toward SP cells under the selective pressure of these treatments, sorted non-SP cells (purity 499%) were treated as above (2 mg/ml Fludarabine for 7 days) before the analysis of the SP phenotype.
A minority of cells (initially exhibiting a non-SP phenotype) survived in these experiments, and virtually all the drugsurviving cells exclusively displayed the SP phenotype (Figure 2d) .
To validate further, our in vitro-based concept of chemoresistant B-CLL SP cells, we analyzed the CD19 þ /CD5 þ SP percentage of five patients before and within 1 year after Fludarabine-based therapy ( Table 2 ). These patients were either relapsing or showing incomplete response after treatment. Except for one patient showing decreased SP percentages after therapy, a global increase of the SP percentage was observed for the four remaining patients, who experienced therapy within the year preceding analysis (Table 2 and Figure 2e ). The median leukemic SP percentage in post-therapeutic patients reached a level considerably higher than what was observed for untreated patients (0.43 versus 0.04%, before therapy).
Together, these results highlight the high level of resistance of SP cells toward multiple chemotherapeutic agents. These in vitro data are further supported by the significant amount of SP cells present after chemotherapy in patients undergoing relapse or displaying persistent leukemic cells. In addition, 
B-CLL SP and non-SP cell dynamics
We finally aimed at characterizing the dynamics of SP and non-SP populations in B-CLL. More precisely, we asked whether proliferating SP cells could refuel the main compartment of non-SP cells. B-CLL cells are inherently quiescent and their proliferation in vivo is a finely tuned process. 25 In order to investigate the refuelling capacity of SP cells, we used the powerful proliferative trigger DSP30 (CpG-ODN) and IL-2 23,24 as a molecular tool to induce B-CLL proliferation in vitro. First, we tested the ability of this combination to induce proliferation of B-CLL SP cells. B-CLL cells loaded with carboxyfluorescein succinimidyl ester were induced to proliferate by DSP30 and IL-2. The cells were cultured in vitro for 7 days before measuring the division by flow cytometry in conjunction with detection of SP and non-SP fractions. This method enabled us to assess division through carboxyfluorescein succinimidyl ester dilution in both CD19 þ CD5 þ SP and non-SP cells from six B-CLL patients. As expected, the bulk of B-CLL cells, which is essentially composed of non-SP, proliferated vigorously on stimulation with DSP30 þ IL-2, whereas untreated cells did not divide at all. Most importantly, the stimulus had also triggered division of the SP cells (Figure 3a) . Sorted SP cells (from n ¼ 3 B-CLL patients) were then induced to divide as above and then analyzed for SP phenotype after in vitro culture. After 7 days of stimulation, the phenotype of all samples of SP-sorted cells revealed both SP and non-SP cells (Figure 3b ). Varying proportions of these compartments were observed with the different samples (non-SP median ¼ 15.9%, range: 4.25-29%), suggesting that proliferating SP cells refuelled the non-SP compartment on division. Finally, once stimulated as above, the Fludarabine-induced SP cells were also able to regenerate non-SP cells (non-SP median ¼ 71%, range: 56,4-99%) (Figure 3c ).
Together these observations indicated that in B-CLL, both mitotic division and chemotherapeutic adaptive evolution can drive a bidirectional dynamics refuelling both SP and non-SP cell compartments.
Discussion
This study aimed at elucidating the cellular basis of B-CLL chemoresistance. Confirming a recent publication, 22 here we reported the existence of few natural SP cells in virtually all B-CLL patients, which harbors phenotypic and cytogenetic hallmarks of the disease. Although they are chemoresistant, B-CLL SP cells are present in patients before any treatments. In our in vitro model, the SP phenotype appeared as an essential feature to survive drug treatment, making chemotherapy a potent screening for such cells. Indeed, B-CLL highly depleting therapies, inducing a massive cell death of the overall B-CLL population, selected exclusively for acquired and innate SP cells. Supporting this in vitro cellular pathway of B-CLL chemoresistance, most post-therapeutic samples, from patients either relapsing or showing an incomplete response, exhibit a high percentage of leukemic SP cells. Finally, both mitotic division of innate SP cells and chemotherapy-induced emergence of acquired SP cells are able to refuel both SP and non-SP cell compartments of the B-CLL disease. Three issues are raised by these findings.
First, the stemness of cancer SP cells has long been debated, 26 although this question had not been addressed in B-CLL so far. Here, the specific phenotype of B-CLL SP cells, which was formally validated by ABCG2 and BMI-1 expressions, 20, 27 was nevertheless quite incomplete as lacking typical cell surface markers of immaturity (for example, CD34, CD127). 28 However, B-CLL is a malignant disease of phenotypically mature B cells, in which clonal progeny naturally lacks expression of immaturity antigens. 25 Likewise, SP cells from other mature B-cell malignant hemopathies, such as multiple myeloma, also present phenotypes inherent to the differentiation status of their non-malignant counterpart. 21 The increased level of CD38 expression, which here typified B-CLL SP cells from CD38 þ patients, is usually observed for highly proliferating B-CLL cells 29 and correlates with a poor clinical outcome, 30 supporting the view that B-CLL SP cells are important for progression of the disease. The fact that whether in vitro SP cells exposed to pertinent stimuli and microenvironmental cells 31 actually undergo more mitosis than the bulk of quiescent B-CLL cells remains elusive, although likely. There is now a large amount of scientific evidence suggesting that the proliferating pool of B-CLL cells is localized into specialized structures in the lymph nodes called the proliferation centers. In this specific surrounding microenvironment, the B-CLL cells contained in the proliferation centers display high proliferative capacity (Ki67 þ ) and increased expression of antiapoptotic proteins. 32 We are planning to investigate the SP phenotype of the leukemic cells present in the proliferation centers 'feeding' the B-CLL population in the peripheral blood.
Demonstrating the leukemic-initiating activity of human B-CLL SP cells in vivo; however, for example, by regenerating the whole human disease in mice models xenografted with human SP cells still remains out of reach. Related experiments, Staging was according to Binet staging system. c WBC was expressed as cells/ml of blood.
Innate and acquired chemoresistant B-CLL SP cells E Gross et al using drug-surviving cells, have successfully been performed for human lung cancer xenografts, 33 but the human B-CLL dependence to local immune microenvironments for survival and growth cannot be met or adequately reconstituted in immunodeficient mice. New murine models deleted for miR-15a/16-1, which develop a B-CLL-like pathology, 34 might represent a new option to fully validate the leukemic-initiating potential of B-CLL SP cells in vivo.
Second, this study uncovered the heterogeneity of the SP compartment, by evidencing two distinct subsets of chemoresistant SP cells; the innate pool, which exists in patients before treatment, and its acquired counterpart, which differentiates on chemotherapeutic pressure. These compiled findings and the increased proportion of SP cells observed in post-therapeutic patients suggest that current therapeutic options are ineffective 8 and platinium. 33 In complete accordance with our findings, ABCG2 ectopic expression has been shown to mediate Fludarabine resistance, 36 and B-CLL SP cells have been shown to resist Fludarabine treatment. 22 Our study is the first report which, to our knowledge, extends SP resistance to Bendamustin, an alkylating agent, and Rituximab, a monoclonal antibody. Although we assume that the molecular basis of chemoresistance to Fludarabine and Bendamustin is relying on activity of ABC transporters, which efflux drugs and Hoechst 33342 dye, 36 resistance to Rituximab rather involves additional drug-resistance mechanisms, such as the inhibition of the apoptotic process. This study also demonstrated that some non-SP may switch to SP under chemotherapy, generating what we referred here to as adaptive SP cells. Indeed, this presumably þ CD5 þ population.
Innate and acquired chemoresistant B-CLL SP cells E Gross et al corresponds to the well-established, classical mode of chemotherapeutic resistance based on the upregulation of ABC transporters by cells escaping to apoptosis. Under such circumstances, the expression of ABCB1 mRNA was known to globally enhance among surviving cells 7, 37, 38 by adaptation to the drug. From our above data, we now conclude that B-CLL chemoresistance not only relies on the mere upregulation of efflux pump by some evolving cells, but also involves the cellular heterogeneity reflected by both natural and acquired subsets of SP cells.
Third, we uncover here a dynamics of B-CLL sub-populations regeneration susceptible to account for repetitive B-CLL posttherapeutic relapses. Untreated B-CLL patients comprise at diagnostic a bulk of circulating CLL cells composed of non-SP plus rare innate SP cells. Mitotic divisions of this bulk, either induced by DSP30/IL-2 in vitro or by physiological stimuli extrapolated in vivo, 31 do self-perpetrate this heterogeneity observed in all patients. By contrast, chemotherapy massively destroys most non-SP cells and selects SP cells only, which are either innately resistant SP or newly adapted SP cells. Furthermore, the downstream proliferation of chemoresistant SP cells regenerates partially the non-SP compartment of the B-CLL disease.
To conclude, this report pinpointed two SP cell subsets as critical determinants of B-CLL chemoresistance. Hence, future studies identifying means to eradicate these populations will bring significant progress to improve the efficiency of B-CLL therapy.
